Chiya Oshiro
Kaizuka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
Journal: Breast cancer (Tokyo, Japan)
Published: January 27, 2026
Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.
Journal: Breast cancer (Tokyo, Japan)
Published: August 18, 2025
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: June 23, 2025
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: January 28, 2025
Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
Journal: Breast cancer (Tokyo, Japan)
Published: December 03, 2024
Development of a prediction model for ctDNA detection (Cir-Predict) in breast cancer.
Journal: Breast cancer research and treatment
Published: June 24, 2024
Receptor discordance after nipple-sparing mastectomy.
Journal: Surgery in practice and science
Published: February 28, 2024
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Journal: Breast cancer (Tokyo, Japan)
Published: December 28, 2023
Patient Preference for Surgical Methods for Ipsilateral Breast Tumor Recurrence.
Journal: Annals of surgical oncology
Published: December 05, 2023
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Journal: Breast cancer (Tokyo, Japan)
Published: January 31, 2023
Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy.
Journal: In vivo (Athens, Greece)
Published: January 14, 2023
Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.
Journal: Annals of surgical oncology
Published: August 10, 2022
Last Updated: 09/26/2026